Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced in Q2 CY2025, with sales up 10.3% year on year to $14.65 billion.

Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.

In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...